Astragalus Mongolians' Suppression of HBV DNA Level in ChronicHepatitis B (CHB) Patients with Moderately Increased AlanineAminotransferase (ALT)

Abstract

This paper aims to examine the impact of Astragalus on the quantity of HBV DNA in chronic hepatitis B (CHB) patientswith slightly raised ALT and the effect on IFN-G. Moreover, the work predicted that IFN-gamma would increase aftertaking Astragalus Mongolians in CHB mouse patients with mildly raised ALT and effectively suppress the amount ofHBV DNA. Three groups of mice were set up, including a positive control group, a negative control group, and a groupof mice with mildly elevated ALT, which are more significant than one to two times the upper limit of normal (1-2 timesULN) and carrying CHB. Astragalus was administered to mice previously infected with HBV in increasing doses andfor longer lengths of time. Entecavir was a positive control, while PBS + DMSO was the negative control. IFN-g in theblood was detected using an ELISA test, and HBV DNA was determined using RT-PCR. The six possible results in thispaper correspond to the reaction of CHB-carrying mice with mildly elevated ALT to Astragalus. Whether the amount ofIFN-G and HBV DNA was elevated or reduced. The results of this paper will effectively predict the effect of Astragaluson the amount of HBV DNA in CHB-carrying mice with mildly raised ALT with several different outcomes. This paperalso analyzes the different outcomes and compares the changes in IFN-G; corresponding conclusions will be drawnbased on the different outcomes.